Based on this finding, we suggest that most VPS4B‐deficient cancer cells would not avert cell death upon therapeutic VPS4A perturbation, irrespective of their individual genetic or epigenetic alterations in one or more death pathways that may appear in a heterogenic tumor mass. This evidence concerns the gene VPS4A and neoplasm.